儿童患者的早期数据与之前在成人参与者中观察到的积极结果一致。研究首席研究员Tomas Aleman医学博士指出，患者感知亮度、识别字母和独立导航的能力有所提高。Opus Genetics首席执行官George Magrath医学博士对OPGx-LCA5恢复LCA5患者显著视力的潜力表示乐观。

H.C. Wainwright的分析师对公司在IRD管线和更广泛的合作开发方面的持续进展表示乐观。这一积极展望支持了该公司重申Opus Genetics股票"买入"评级和8美元目标价的决定。该公司市值为4415万美元，交易价格低于其 InvestingPro 公允价值，寻求详细分析的投资者可以通过 InvestingPro 订阅获取额外的财务指标和10个更多的专业提示。

遗传性视网膜疾病（IRDs）是一类致盲性罕见病，遗传异质性高，南亚人群相关研究匮乏。研究人员对巴基斯坦 213 个 IRD 家庭进行全外显子测序。发现独特突变谱，诊断率达 80.3% 。该研究为当地遗传分析、咨询及基因治疗提供重要依据。

Inland Revenue has collected $600 million in extra taxes from 3,600 audits between July and December last year – 50% more ...

Opus Genetics (IRD) announced one-month clinical data from the first pediatric patient treated with its investigational gene therapy, ...

The new data builds upon previously reported 6- and 12-month positive results from adult patients treated in the same study.

Opus Genetics (IRD) announced through a letter to Opus stockholders that it has mailed definitive proxy materials to stockholders in connection ...